Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLA-mismatched allogeneic HSCT with low-dose alemtuzumab and adjusted immunosuppression
jRCTs031180237Completed
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of alemtuzumab in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), lymphosarcoma and 2 more. Primary endpoint: Primary: Day 60 survival with engraftment and without severe acute GVHD. Started Aug 2015; status: completed.
02
Drugs
alemtuzumab
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)lymphosarcomamyelodysplastic syndrome (MDS)hematopoietic malignancies
Beyond the preview
Go deeper on jRCTs031180237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180237.